Add time:07/13/2019         Source:sciencedirect.com

Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[3,2-c]pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib.

We also recommend Trading Suppliers and Manufacturers of 2-(2,2,2-Trifluoroethoxy)pyridine-3-boronic acid (cas 1218790-79-4). Pls Click Website Link as below: cas 1218790-79-4 suppliers